Loading company
Neogenomics Inc.
NEO · Nasdaq · ·
Next earnings: October 27, 2026
$18.75-2.8%Sep 29 close
- 1M
- +3.9%
- 6M
- +160.4%
- 1Y
- +142.9%
- 5Y
- -60.1%
NEO · Nasdaq · ·
Next earnings: October 27, 2026
$18.75-2.8%Sep 29 close
Neogenomics Inc. is scheduled to report next on October 27, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $201.7M | $181.3M | +11.21% |
| Profit | $2.2M | -$45.1M | +104.96% |
| Profit per share | $0.01 | $0.00 | — |
| Free Cash Flow | $11.7M | $14M | -16.18% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter results reflect the consistent operating and financial performance investors expect from this team,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”). NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912 Page | 2
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neogenomics Inc.’s Item 2.02 8-K filed July 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Neogenomics Inc. has no earnings call transcript available.